{"name":"Plexium, Inc.","slug":"plexium-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4xMHVKU1RITHdrZjVaUW1md05BUnU3UzhLMG82YXJHUWtDYnpMTDFEU051UjVWVlFDLTcyb3dpQTZQcTVnempQbmM0ekhjeVBPVlp2NDJyMHl1QllIR3ZF?oc=5","date":"2026-01-13","type":"trial","source":"nature.com","summary":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson - nature.com","headline":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxNZnNVT2NUdldOdUZUSXZ0WGZsaDNpakJlMFN0eHhZNkppRGZrUmtRWGxYRU9EOTBGbTlMVjhfV3V4d00xcndNUllDUlFHTUlpNHZBbDlTSEVkY1lxaW9Mbl8zMWZpUnBlUkM4UkRIcnNLS0doUEFHbHFEV19kUERqamFBdkVLSldRR0dDTWE0bzlVQW5GTl84WVo1YmdOOTk1THI3QmVBQWxlRnZyM2ZibXBiZnlDaGtxQmNraEVnclRQZ3N6MnNtNGNPMUxEVE5VUEUtcEl1UmViU1lFb3ZYQnFOYUZEUUtXTW93em1WM3dZWHI2THVCaTRXN1VuZ2FaaWVtaG1zTTJrZjJBbk0zbHRTcE0?oc=5","date":"2025-04-28","type":"pipeline","source":"PR Newswire","summary":"Plexium Announces Multiple Presentations at AACR 2025 with Selective Monovalent Degrader Programs Targeting SMARCA2, IKZF2 and CDK2 - PR Newswire","headline":"Plexium Announces Multiple Presentations at AACR 2025 with Selective Monovalent Degrader Programs Targeting SMARCA2, IKZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNSlh2ODVLTnJ5NnRfdjUxMmVWWXptdzduSVo0RmJEdXZfSWFpdEFEMk9EY0hjTk10OUhZVWJFaFBnMjZDTjU5b0hNUGlLN2xPWmZYeHphdnljam9zbE1jTHJVWVE4Q1B6VUx5eTR2T2JwNVRTNFVSNkFJdTVXcm5veDZQbUphclJXMlUwejdvejRXNlREbXMwZjVFSGV0YnRpa2lsTnJaVFEtVXpLWjYxN08xZ3JfQVVNVjB5MFdMSTd6RVN0RzVVVzF6SS0tZ3ZOYWZDT1pRRkNrWFc2N3ZEWUZZTmFHZ2RqaXlsSlMzN0ExV3hnbGQ0Wg?oc=5","date":"2024-11-20","type":"pipeline","source":"globenewswire.com","summary":"Unnatural Products Appoints Simon Bailey, Ph.D., as Chief Operating Officer and President of R&D - globenewswire.com","headline":"Unnatural Products Appoints Simon Bailey, Ph.D., as Chief Operating Officer and President of R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNSFZNeE9XMEpNdXI4ak1scmdma1FFUi13Z202ZDQxcFhEUzRDcW1BZDlBOWV5eTBfeExLWHZ1MzZHY1RSeV90Z09HR0JFZVJvUkRTZlA3OW0zZjRyUndKUk5iWlJFcEFYd3pVbkN4anZMX09LWm91VGZUOVlkaUF4eE1qRHg2TjFTQnBYbFpIc0MzeXM3NEx5aTZ1eEp1X0dnTUhDMVZGWmdIOFNzX1JxZ2tPNy04SHZONy1LQ3dMTHE4V29vTXFqLUFaWi1vZG11X1RKSg?oc=5","date":"2024-10-01","type":"pipeline","source":"PR Newswire","summary":"Plexium Announces Appointment of Jorge F. DiMartino, M.D., Ph.D. as Chief Medical Officer - PR Newswire","headline":"Plexium Announces Appointment of Jorge F. DiMartino, M.D., Ph.D. as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQTDVMQlFDLVVfc2owelUyRmthVVdqd1N6RDNITEpBYWpheGlfTFhQbEZVaUJxNUQyaUI3NXhlT3UzWG1RMVl5cFhqRWlLZlJJMXJOc2hKMXdvQUl6TDJiWlpHZThDV3dpbmRMZmZPbnBSRHZtSkU5RnBsZzg3MkJZdmIyT1dCUU9xSEJZX0h6WUZ1R2JhdVRiNjNacHRHc3QxZld0Q2lRalNiRHB3N3NYTXY4SlNlejRCcjlmZDQ2ZjRZSzJrZHNz?oc=5","date":"2024-01-16","type":"pipeline","source":"PR Newswire","summary":"Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO - PR Newswire","headline":"Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQd3QxUHlXNHE1QjA2MUl6Y0ZhbnQwY3lfTWVQMVJOcmlfZHB6ZlA2bmFhVEZZOVNxNmJ1ZjFkS1Jtd09MQjd2dC1qbDRtTmpBNG1MZlhNdUZ0ZGxMLU9mQ2llVlNWdnllcEJfME9PTnA2Q05wOG1pNGd4MVBsSFRnMGFScW9IdWlJUjBObGtNSmoxWndsbVpZOTlSaE10ZW1lbTlMaGtKUlBBOWFGemtWZXJ6TXpmM3liUjNXbVdERDA3eHFaYW54bldVQjJzRm5yUWZ2aXpXNlBoblVRZUE3bWM3T3BUMXQ4RXIydVQ1NE1CX2E1YUtBNnB6R3o5SHpNX3BDMWZn?oc=5","date":"2023-12-12","type":"trial","source":"PR Newswire","summary":"Plexium Initiates Dosing in Phase 1 Study of PLX-4545, a Potent and Selective Degrader of the Transcription Factor IKZF2 - PR Newswire","headline":"Plexium Initiates Dosing in Phase 1 Study of PLX-4545, a Potent and Selective Degrader of the Transcription Factor IKZF2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxQTjFiWEF5WjZkVVYwWVFRUGNiUEd3STk2alJ1STR6TVJkbkZCek1reXNyam1qMUxBUTMtb3Jla0FkTEpwZnd3Q2g0VjgtVTRwazZibG1ReTlQc0NQNTNZblhhTGFhTjdtdno4TzdEbV9oN0FqXzRRTzlDZ2psU2NIU2pScFJBZG5xRDVwS0V5Rk03YjBISG9OV1puRGFiT05hbVFIVTZ4Q3V6aHhwYlVMQTFBLVBsWHY3dEs0TFlXQWpTVExMMDdtd2M0UGl5R2NlaF96SlgxTTdHMkZ5UjIwNzZ4d1NBc1QzV1VOeEZTR1JVZDNUV0RYbGRwLUZCX1RQX2VpaA?oc=5","date":"2022-02-23","type":"pipeline","source":"PR Newswire","summary":"Plexium Announces $102M Financing To Advance Pipeline Of Targeted Protein Degradation Therapies And Technology Platform - PR Newswire","headline":"Plexium Announces $102M Financing To Advance Pipeline Of Targeted Protein Degradation Therapies And Technology Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOQlpLMzRxRTltYkg4QVpIaVllWlRFWFA0dnFsaGk4dkVUSV9yZ0VRYncxcFN5NEYyZFJKUV9XcXJheFBjSGVoR2wza1BTeDRwT28xQlk4bVJkbEpVeWs0ZFBkbHJGMzVQcGVLNlhNcHYxVWtoSTJwSjcyOUxNR0xQdHBoMHZ4VmhPMTkwNU1vOGhCQUdBUDNmbnpaQ3NqQkdPMDRJTjZnLUM0TmV2SzRwWHRkRQ?oc=5","date":"2022-02-03","type":"deal","source":"Fierce Biotech","summary":"Amgen enters hot protein degradation field with $500M biobucks deal with Plexium - Fierce Biotech","headline":"Amgen enters hot protein degradation field with $500M biobucks deal with Plexium","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPYi1XYksxbGF4aWtLbUltUXAxWEFHYXZfQTZvUmJNbi1sUldnSGhnY2tQb0hzRE4yYl9pS1VtWGE0WlQ1RXNaWFl3WTVWcUxaODlyZEk3UUx4TVRMZ0xGN0RHU2YwTEthNmJaZkNsN1lNZHY1OXhJYWlkRXV3UkhYM3oycGRRSnZsWUpMV2hQS0NINXc4eWcxZVdSZw?oc=5","date":"2022-02-03","type":"pipeline","source":"BioSpace","summary":"Amgen and Plexium Ink $500M Targeted Protein Degradation Therapies Pact - BioSpace","headline":"Amgen and Plexium Ink $500M Targeted Protein Degradation Therapies Pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxOQ01Ra19DQVR3YUVWSjBCYVM0U3U3Y0F6MUhDbHlpTTYyNHlEV1BRSHVNLTVsT0VINFdyV1BzZUxYa0xyQlgzZG5BYUlXMVNWcWRKWmFscW9xbFRwYWxUUlg0RVN6UkRnY2owX3g1aUQzMEQ0YThmYzIzUDNiMW55a05MZ05RR1BXSFFXT0l3a2ItS3JzWjVyMHEyT2hYNnJEZVR6VDZUMUF6S25fT1hIZVVObUJWc2xEZVEtVjF1dmFBM0Q5ZE9jTG9idGJKajAzbVhTQVkwQW1vYVBpMGlOYzBOeDBobkJLRDlGRU5IU3RDMnZEUzZjaGc2TVd6UW1PNmViNGVOYkRmNVE?oc=5","date":"2022-02-03","type":"deal","source":"PR Newswire","summary":"AMGEN AND PLEXIUM ANNOUNCE MULTI-YEAR, DRUG DISCOVERY COLLABORATION TO IDENTIFY NOVEL TARGETED PROTEIN DEGRADATION THERAPIES - PR Newswire","headline":"AMGEN AND PLEXIUM ANNOUNCE MULTI-YEAR, DRUG DISCOVERY COLLABORATION TO IDENTIFY NOVEL TARGETED PROTEIN DEGRADATION THERA","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}